Article (Scientific journals)
Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.
Hiligsmann, Mickaël; Ben Sedrine, Wafa; REGINSTER, Jean-Yves
2013In Journal of Bone and Mineral Research, 28 (4), p. 807-15
Peer Reviewed verified by ORBi
 

Files


Full Text
Cost-effectiveness of Bazedoxifene.pdf
Publisher postprint (405.21 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Bazedoxifene is a novel selective estrogen receptor modulator (SERM) for the prevention and treatment of osteoporosis. In addition to the therapeutic value of a new agent, evaluation of the cost-effectiveness compared with relevant alternative treatment(s) is an important consideration to facilitate healthcare decision making. This study evaluated the cost-effectiveness of bazedoxifene compared with raloxifene for the treatment of postmenopausal women with osteoporosis. The cost-effectiveness of treatment for 3 years with bazedoxifene was compared with raloxifene using an updated version of a previously validated Markov microsimulation model. Analyses were conducted from a Belgian healthcare payer perspective and, the base-case population was women (aged 70 years) with bone mineral density T-score </= -2.5. The effects of bazedoxifene and raloxifene on fracture risk were derived from the 3-year results of a randomized, double-blind, placebo-controlled and active-controlled study, including postmenopausal women with osteoporosis. The cost-effectiveness analysis based on efficacy data from the overall clinical trial indicated that bazedoxifene and raloxifene were equally cost-effective. When the results were examined based on the subgroup analysis of women at higher risk of fractures, bazedoxifene was dominant (lower cost for higher effectiveness) compared with raloxifene in most of the simulations. Sensitivity analyses confirmed the robustness of the results, which were largely independent of starting age of treatment, fracture risk, cost, and disutility. In addition, when the cost of raloxifene was reduced by one-half or when incorporating the raloxifene effects on reducing breast cancer, bazedoxifene remained cost-effective, at a threshold of euro35,000 per quality-adjusted life-years gained, in 85% and 68% of the simulations, respectively. Under the assumption of improved antifracture efficacy of bazedoxifene over raloxifene in women with high risk of fractures, this study suggests that bazedoxifene can be considered cost-effective, and even dominant, when compared with raloxifene in the treatment of postmenopausal osteoporotic women.
Disciplines :
General & internal medicine
Author, co-author :
Hiligsmann, Mickaël ;  Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Ben Sedrine, Wafa ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
REGINSTER, Jean-Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Language :
English
Title :
Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.
Publication date :
2013
Journal title :
Journal of Bone and Mineral Research
ISSN :
0884-0431
eISSN :
1523-4681
Publisher :
Wiley-Blackwell, Washington, United States - District of Columbia
Volume :
28
Issue :
4
Pages :
807-15
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2013 American Society for Bone and Mineral Research.
Available on ORBi :
since 31 July 2013

Statistics


Number of views
60 (4 by ULiège)
Number of downloads
2 (2 by ULiège)

Scopus citations®
 
11
Scopus citations®
without self-citations
7
OpenCitations
 
9

Bibliography


Similar publications



Contact ORBi